Letters
New drugs for hyponatraemia
Cost effectiveness of tolvaptan
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d1947 (Published 29 March 2011) Cite this as: BMJ 2011;342:d1947
- Paul Grant, physician
- 1Department of Endocrinology, King’s College Hospital, London SE5 9RS, UK
- drpaul.grant{at}doctors.org.uk
Amin and Meeran refer to the relative expense of tolvaptan, one of the new vasopressin 2 receptor antagonists.1 They suggest that it has little benefit over existing treatments but fail to mention …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.